SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals reports 18% rise in Q3 profit before tax

12 Mar 2012 Evaluate

Alembic Pharmaceuticals has reported results for third quarter ended December 31, 2011.

The company has posted a rise of 15% in its net sales at Rs 383 crore for the quarter ended December 31, 2011 as compared to Rs 332 crore in corresponding quarter last year. The profit before tax was up by 18% at Rs 53.54 crore for the quarter under review as compared to Rs 45.40 crore in corresponding quarter last year.

Domestic formulations were up 8% at Rs 199 crore against Rs 184 crore in corresponding quarter last year. International generics were up by 13% to Rs 58 crore compared to Rs 52 crore last year.

The company has received approval for 2 ANDA in current quarter while 3 DMF’s were filed during the quarter.

Alembic Pharma Share Price

723.95 3.90 (0.54%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×